Literature DB >> 12556225

Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme.

Meng-Huee Lee1, Philippa Dodds, Vandana Verma, Klaus Maskos, Vera Knäuper, Gillian Murphy.   

Abstract

Tumour necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) is a membrane-anchored, multiple-domain zinc metalloproteinase responsible for the release of the potent pro-inflammatory cytokine, TNF-alpha. The extracellular part of the active enzyme is composed of a catalytic domain and several cysteine-rich domains. Previously, we reported that these cysteine-rich domains significantly weakened the inhibitory potency of the N-terminal-domain form of tissue inhibitor of metalloproteinases-3 (N-TIMP-3). In the present paper, we describe a novel strategy developed to overcome this weakening effect. We have engineered a new generation of N-TIMP-3 mutants that are capable of withstanding the repulsion of the cysteine-rich domains by the formation of electrostatic bonds with the catalytic domain of the enzyme. These N-TIMP-3 mutants displayed markedly improved binding affinity with the soluble extracellular domain form of recombinant TACE. With K (i) (app) values of <0.1 nM, these mutants were dramatically better than the wild-type N-TIMP-3 [K (i) (app) 1.7 nM]. We accounted for this by proposing that Glu(31), an acidic residue situated at the base of the AB-loop of N-TIMP-3, is drawn into contact with Lys(315), a prominent basic residue adjacent to the TACE catalytic site. The mutagenesis strategy involved reorientation of the edge of N-TIMP-3; in particular, the beta-strand A where Glu(31) was located. Further expression of one of the mutants, Lys(26/27/30/76)-->Glu, in a mammalian expression system confirmed that TIMP-3 associates with the extracellular matrix via its C-terminal domain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556225      PMCID: PMC1223312          DOI: 10.1042/BJ20021538

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE).

Authors:  M E Milla; M A Leesnitzer; M L Moss; W C Clay; H L Carter; A B Miller; J L Su; M H Lambert; D H Willard; D M Sheeley; T A Kost; W Burkhart; M Moyer; R K Blackburn; G L Pahel; J L Mitchell; C R Hoffman; J D Becherer
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

2.  Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway.

Authors:  Mark Bond; Gillian Murphy; Martin R Bennett; Andrew C Newby; Andrew H Baker
Journal:  J Biol Chem       Date:  2002-02-04       Impact factor: 5.157

3.  Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity.

Authors:  M Bond; G Murphy; M R Bennett; A Amour; V Knauper; A C Newby; A H Baker
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

4.  NMR structure of tissue inhibitor of metalloproteinases-1 implicates localized induced fit in recognition of matrix metalloproteinases.

Authors:  B Wu; S Arumugam; G Gao; G I Lee; V Semenchenko; W Huang; K Brew; S R Van Doren
Journal:  J Mol Biol       Date:  2000-01-14       Impact factor: 5.469

5.  Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase.

Authors:  M H Lee; V Knäuper; J D Becherer; G Murphy
Journal:  Biochem Biophys Res Commun       Date:  2001-01-26       Impact factor: 3.575

6.  Characterization of a transformation-sensitive protein in the extracellular matrix of chicken embryo fibroblasts.

Authors:  J Blenis; S P Hawkes
Journal:  J Biol Chem       Date:  1984-09-25       Impact factor: 5.157

7.  Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme.

Authors:  Meng-Huee Lee; Vandana Verma; Klaus Maskos; Deepa Nath; Vera Knäuper; Philippa Dodds; Augustin Amour; Gillian Murphy
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

8.  The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3.

Authors:  Meng-Huee Lee; Vandana Verma; Klaus Maskos; J David Becherer; Vera Knäuper; Philippa Dodds; Augustin Amour; Gillian Murphy
Journal:  FEBS Lett       Date:  2002-06-05       Impact factor: 4.124

9.  Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering.

Authors:  Meng-Huee Lee; Klaus Maskos; Vera Knäuper; Philippa Dodds; Gillian Murphy
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

10.  The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases.

Authors:  G Murphy; F Willenbrock; R V Ward; M I Cockett; D Eaton; A J Docherty
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

View more
  5 in total

Review 1.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

Review 2.  Evolutionary families of peptidase inhibitors.

Authors:  Neil D Rawlings; Dominic P Tolle; Alan J Barrett
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

Review 3.  Pericellular proteolysis in cancer.

Authors:  Lisa Sevenich; Johanna A Joyce
Journal:  Genes Dev       Date:  2014-11-01       Impact factor: 11.361

Review 4.  Genetic basis of inherited macular dystrophies and implications for stem cell therapy.

Authors:  Carla B Mellough; David H W Steel; Majlinda Lako
Journal:  Stem Cells       Date:  2009-11       Impact factor: 6.277

Review 5.  The ADAM metalloproteinases.

Authors:  Dylan R Edwards; Madeleine M Handsley; Caroline J Pennington
Journal:  Mol Aspects Med       Date:  2008-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.